- By Adjoa Kyerematen
Rep. Robin Kelly admits that the word “diversity” has scared some of her Republican colleagues away from her effort to improve representation in clinical trials.
“It’s been a little tough on the other side of the aisle,” Kelly said at a recent STAT event. “I don’t want to put one broad brush on everybody, but … they feel like the government’s putting their nose in something a little bit too much.”
The Illinois Democrat has already managed to get one GOP co-sponsor on board with her bill, the NIH Clinical Trial Diversity Act of 2022, which would require clinical trial sponsors to write formal diversity plans when they apply for funding from the National Institutes of Health. If it passes, the bill would also hold pharmaceutical companies responsible for a clear strategy to recruit and retain people largely underrepresented in trials. It would also apply anti-discrimination rules to clinical trials.
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Subash Kafle
- Victor Mejia
- Victor Mejia
